ATE205531T1 - Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum - Google Patents

Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Info

Publication number
ATE205531T1
ATE205531T1 AT94909270T AT94909270T ATE205531T1 AT E205531 T1 ATE205531 T1 AT E205531T1 AT 94909270 T AT94909270 T AT 94909270T AT 94909270 T AT94909270 T AT 94909270T AT E205531 T1 ATE205531 T1 AT E205531T1
Authority
AT
Austria
Prior art keywords
inhibition
growth
cell activation
antibodies
cd2a
Prior art date
Application number
AT94909270T
Other languages
English (en)
Inventor
Herve Bazin
Dominique Latinne
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Application granted granted Critical
Publication of ATE205531T1 publication Critical patent/ATE205531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94909270T 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum ATE205531T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2700893A 1993-03-05 1993-03-05
US11903293A 1993-09-09 1993-09-09
PCT/IB1994/000043 WO1994020619A1 (en) 1993-03-05 1994-03-04 LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION

Publications (1)

Publication Number Publication Date
ATE205531T1 true ATE205531T1 (de) 2001-09-15

Family

ID=26701922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909270T ATE205531T1 (de) 1993-03-05 1994-03-04 Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Country Status (10)

Country Link
EP (1) EP0687300B1 (de)
JP (2) JP3711143B2 (de)
AT (1) ATE205531T1 (de)
AU (1) AU686600B2 (de)
CA (1) CA2157500C (de)
DE (1) DE69428272T2 (de)
DK (1) DK0687300T3 (de)
ES (1) ES2164699T3 (de)
PT (1) PT687300E (de)
WO (1) WO1994020619A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
ATE432080T1 (de) * 1996-08-16 2009-06-15 Biotransplant Inc Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
CN100497610C (zh) 1996-12-06 2009-06-10 阿温蒂斯药物公司 人脂酶样基因编码的多肽及利用它的组合物和方法
JP4808841B2 (ja) * 1997-07-18 2011-11-02 バイオトランスプラント，インコーポレイテッド Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法
WO1999025367A2 (en) 1997-11-14 1999-05-27 The General Hospital Corporation Treatment of hematologic disorders
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
KR101240206B1 (ko) 2010-10-05 2013-03-06 고려대학교 산학협력단 자연살상 세포-매개 면역반응 억제용 조성물
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
EA202090922A1 (ru) * 2017-11-29 2021-03-09 Маджента Терапьютикс, Инк. Композиции и способы истощения cd2+ клеток
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody

Also Published As

Publication number Publication date
DK0687300T3 (da) 2001-12-31
JP4195453B2 (ja) 2008-12-10
DE69428272T2 (de) 2002-06-27
AU686600B2 (en) 1998-02-12
JP2005239725A (ja) 2005-09-08
AU6218194A (en) 1994-09-26
PT687300E (pt) 2002-03-28
EP0687300B1 (de) 2001-09-12
JP3711143B2 (ja) 2005-10-26
WO1994020619A1 (en) 1994-09-15
CA2157500A1 (en) 1994-09-15
DE69428272D1 (de) 2001-10-18
ES2164699T3 (es) 2002-03-01
CA2157500C (en) 2005-08-16
EP0687300A1 (de) 1995-12-20
JPH08507438A (ja) 1996-08-13

Similar Documents

Publication Publication Date Title
EP1003552A4 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGENE ZUR HEMMUNG VON T-ZELL AKTIVIERUNG UND WACHSTUM
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DE69129990D1 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
ATE132197T1 (de) Monoklonale antikörper
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DK0859957T3 (da) Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
FI893428A7 (fi) TNF-a:n in vitro ja in vivo toksisten ominaisuuksien eliminointi monoklonaalisilla vasta-aineilla ja niistä johdetuilla fragmenteilla
NO973875L (no) Fremgangsmåte for stimulering av en immunrespons
FR2677653B1 (de)
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
DE69131253D1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69221605D1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE3850750D1 (de) Verfahren zur Verhütung von GVHD.
DE69010897D1 (de) Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin.
EP0321094A3 (de) Behandlung von Faktor-VIII-Inhibitoren
RU94026276A (ru) Рецепторы интерлейкина-12 и антител

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee